Inito, a Bengaluru-based medical technology start-up, has announced a $6 million Series A funding round led by Fireside Ventures. Inito’s flagship product – Fertility Monitor is a home test that helps women track fertility hormones in 10 minutes and provides advanced personalised analytics about women’s reproductive health.  

The company was launched in 2015 with an aim to build empowering tools for individuals to actively manage and understand their health at home. After 5yrs of R&D, the company launched globally in mid-2021 and has already created a remarkable impact. Inito’s users have already reported over 10,000 pregnancies, taken over 2.5 million tests, and rated it the best fertility test on Amazon, it said in a statement. 

The technology used by the start-up uses a combination of hardware, biotechnology, and machine learning to improve the accuracy, reliability, and density of test strips allowing them to measure multiple parameters on a single testing platform. Its data has been peer-reviewed in leading scientific journals and the company has several granted patents on its technology, it added. 

The funding will support Inito’s global expansion of its hormone test, building even more advanced analytics using AI and investing in R&D for new tests.  

In a joint statement, Inito’s co-founders, Aayush Rai and Varun AV expressed their excitement about the Series A funding, saying, “We started Inito to bring a variety of tests for fertility and beyond on a single device at home; empowering people with direct access to health information and a better understanding of their bodies. The partnership with Fireside Ventures has not only provided crucial financial backing but also valuable mentorship and strategic guidance, enabling Inito to build a leading consumer health tech brand for the world from India.”